VO - Vanguard Mid Cap Index Fund

NYSEArca - Nasdaq Real Time Price. Currency in USD
-0.75 (-0.48%)
As of 11:51AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close156.40
Bid155.58 x 100
Ask155.65 x 700
Day's Range155.14 - 156.49
52 Week Range138.25 - 164.17
Avg. Volume434,317
Net Assets95.07B
PE Ratio (TTM)N/A
YTD Return-0.04%
Beta (3y)0.97
Expense Ratio (net)0.05%
Inception Date2004-01-26
Trade prices are not sourced from all markets
  • ADP: Another Strong Jobs Report in the Cards This Month
    Market Realist11 days ago

    ADP: Another Strong Jobs Report in the Cards This Month

    ADP, a human capital management solutions provider, releases a monthly report on US non-farm employment. Changes to the level of hiring and gains in employment across different sectors in the United States are captured in the report. ADP processes the payrolls of more than 24 million workers in the United States, which gives the organization a unique insight into the US employment market.

  • ETF Trends2 months ago

    Mid-Cap ETFs Can Get a Weak Dollar Boost

    It is often said that large-caps, many of which are multi-national firms generating significant portions of their revenue overseas, benefit from a weak dollar while smaller companies, due to their domestic ...

  • Mid-Cap Growth ETFs for a Roller-Coaster Market
    Zacks2 months ago

    Mid-Cap Growth ETFs for a Roller-Coaster Market

    Mid caps offer the best of both the worlds, allowing growth and stability in portfolios simultaneously.

  • Reuters2 months ago

    Britain's TalkTalk raises cash, cuts dividend to join the fibre race

    TalkTalk (TALK.L) raised 200 million pounds from investors on Thursday to help fund a plan to connect three million British homes and businesses with ultrafast broadband and keep it competitive with bigger rivals. The British firm said it had provisionally agreed to set up an independent company with M&G Prudential to build the network, with a combined potential equity investment of up to 500 million pounds and borrowing of around 1 billion pounds. "TalkTalk's announcement is a major rolling of the dice to turn around the fortunes of a company dogged by profits warnings and underperformance versus larger peers," said Henry Croft, research analyst at Accendo Markets.

  • Varian Medical Acquires Sirtex for $1.3 Billion: Highlights
    Market Realist3 months ago

    Varian Medical Acquires Sirtex for $1.3 Billion: Highlights

    On January 30, 2018, Varian Medical Systems (VAR) announced that it had signed an agreement to acquire Australia-based Sirtex Medical Limited for 28 Australian dollars per share in cash, amounting to a total purchase price of $1.3 billion. As per the deal, Varian will acquire all outstanding shares of Sirtex, which is listed on the Australian Securities Exchange. Sirtex is a global life sciences company that’s focused on interventional oncology therapies.

  • Analyst Recommendations for Varian Medical Systems before 1Q18
    Market Realist3 months ago

    Analyst Recommendations for Varian Medical Systems before 1Q18

    What to Expect from Varian Medical Systems in 1Q18Analyst recommendations

  • Hot Areas of Last Week and Their ETFs
    Zacks7 months ago

    Hot Areas of Last Week and Their ETFs

    Hopes for Trump's tax reforms, abating North Korea fears, lower-than-expected damage from Hurricane Irma and record stock market highs rekindled the love for U.S. equity ETFs last week.

  • ETF.com7 months ago

    Least Popular ETFs Of The Year

    It may be surprising to hear that in a year in which ETFs are shattering all sorts of records with regard to the amount of money they are taking in, the world's largest exchange-traded fund isn't participating in the bonanza. That's right; the SPDR S&P 500 ETF Trust (SPY), the $242 billion behemoth, has actually had net outflows this year to the tune of $4.2 billion.

  • Market Realist8 months ago

    How Jazz Pharmaceuticals Aims to Boost Vyxeos Sales in 2017

    In early 2017, Jazz Pharmaceuticals (JAZZ) expanded its sales force team from 35 to 55 and expanded its field reimbursement teams to support the commercial launch of Vyxeos in the US.

  • Market Realist8 months ago

    Inside the Efficacy of JAZZ’s JZP-110 in Obstructive Sleep Apnea Trials

    This trial demonstrated the efficacy and safety of JAZZ's JZP-110 in both the MWT and sleep latency tests at all dosages at the end of weeks 4 and 12.

  • Market Realist8 months ago

    Erwinaze Sales May Remain Flat in 2017

    Erwinaze saw net sales worth $49 million in 2Q17, almost flat compared to the drug’s revenues of $50 million in 2Q16.

  • Market Realist8 months ago

    Dental and Healthcare Consumables Grew but Missed Expectations in 2Q17

    In 2Q17, Dentsply Sirona’s (XRAY) Dental and Healthcare Consumables business contributed ~56% to the company’s total revenues and registered sales of ~$554 million.

  • Market Realist8 months ago

    Align Technology Focuses on International Market Strategy

    In 2Q17, Align Technology (ALGN) reported 85,400 Invisalign case shipments in international markets, which is YoY (year-over-year) growth of ~37.4% and sequential growth of ~13.6%. This growth was mainly ...

  • Market Realist9 months ago

    Edwards Lifesciences’ Mitral Regurgitation Segment

    To diversify its focus beyond aortic structural heart conditions, Edwards Lifesciences (EW) acquired CardiAQ Valve Technologies in August 2015.

  • Market Realist9 months ago

    Can Edwards Lifesciences See Robust Net Profit Margin in 2017?

    In its 2Q17 earnings conference call, Edwards Lifesciences (EW) projected 2017 adjusted EPS to fall to $3.65–$3.85, which is higher than the previous $3.43–$3.55.

  • Market Realist9 months ago

    Transcatheter Heart Valve Therapy: Growth Driver for Edwards Lifesciences

    In 2Q17, Edwards Lifesciences’ (EW) Transcatheter Heart Valve Therapy segment reported revenues close to $316 million, which represents year-over-year growth of ~28%.

  • ETF.com9 months ago

    2017's Stock Market Can't Get Stranger

    What's been unusual about this year's market ascent is not how much stocks have risen. A gain of 12% for the SPDR S&P 500 ETF (SPY) through seven months of the year, while impressive, is well within historical norms. Rather, it's been the consistency and uniformity of the rally that has caught everyone off guard. In the ETF world, an investor could almost throw a dart and come up with gains. Everything from mega-caps to large-caps to midcaps to small-caps is up.   

  • Zacks9 months ago

    Will Low Cost ETF Strength Make Vanguard Top Asset Manager Soon?

    Can Vanguard dethrone BlackRock with the help of its low-cost funds and take the seat of the top asset manager?

  • Top Mid-Cap Blend ETFs
    Motley Fool9 months ago

    Top Mid-Cap Blend ETFs

    These mid-cap blend ETFs offer a low-cost way to own a diverse portfolio of mid-cap stocks. Here's how to find the right fit for your portfolio.

  • Shining The Transparency Light On ETFs
    ETF.com11 months ago

    Shining The Transparency Light On ETFs

    Taking advantage of one of the greatest benefits of ETFs—transparency—can lead to some surprising discoveries. Case in point: the world of small-cap ETFs. We’ve discovered that while a number of ETFs call themselves “small-caps,” they really don't have that much small-cap exposure. And that matters, because a fund that isn’t exactly small-cap is going to deliver different risks and different returns than a pure small-cap strategy. Clarifying Terms

  • Market Realistlast year

    Centene Saw Robust Rise in Medicaid Enrollments in 1Q17

    In 1Q17, around 12.1 million members were enrolled in Centene's (CNC) various healthcare plans, which is a year-over-year (or YoY) rise of around 600,000 beneficiaries.

  • Market Realistlast year

    Quest Diagnostics Could Get Greater Share of Laboratory Segment

    With around 50.0% of hospitals being served by Quest Diagnostics (DGX), the company has become a leading player in the fragmented US laboratory market.